Spectral Medical (TSE:EDT) has released an update.
Spectral Medical Inc. has announced robust patient enrollment in the Tigris trial for July, maintaining a strong performance from the beginning of the year and marking a record month equal to June’s achievement. The trial, which is close to full enrollment with just 25 patients remaining, is on track to potentially complete by December 2024. This Phase 3 study is critical for the company’s innovative sepsis treatment device, PMX, which has already seen significant use globally and has received Breakthrough Device Designation from the FDA.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
